Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Ypsomed Holding AG
  6. News
  7. Summary
    YPSN   CH0019396990

YPSOMED HOLDING AG

(YPSN)
  Report
Delayed Swiss Exchange  -  11:30:17 2023-02-07 am EST
182.40 CHF   -1.08%
01/31Civica Welcomes Ypsomed as Injection Pen Partner for Its Affordable Insulin Initiative
CI
01/03Ypsomed Closes Sale of DiaExpert to Mediq Amid Increased Focus on Chronic Conditions
MT
01/03Ypsomed : and Mediq complete the sale of DiaExpert
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Ypsomed, CamDiab Roll Out Automated Insulin Dosing on Abbott's Glucose Monitoring System

11/25/2022 | 01:15am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ABBOTT LABORATORIES 1.12% 111.99 Delayed Quote.1.82%
YPSOMED HOLDING AG -1.08% 182.4 Delayed Quote.9.24%
All news about YPSOMED HOLDING AG
01/31Civica Welcomes Ypsomed as Injection Pen Partner for Its Affordable Insulin Initiative
CI
01/03Ypsomed Closes Sale of DiaExpert to Mediq Amid Increased Focus on Chronic Conditions
MT
01/03Ypsomed : and Mediq complete the sale of DiaExpert
PU
01/03Mediq B.V. completed the acquisition of DiaExpert GmbH from Ypsomed Holding AG.
CI
2022Abbott's freestyle libre 3 integrated with automated insulin delivery system mylife loo..
AQ
2022Abbott Laboratories' FreeStyle Libre 3 Sensor Integrates With Mylife Loop in Germany fo..
MT
2022Global Rally Helps European Stocks Snap Five-day Losing Streak
MT
2022Eli Lilly Ends Insulin Pump Project With Ypsomed
MT
2022Eli Lilly Abandons Insulin Pump Joint Venture With Ypsomed To Focus On Drug Portfolio
MT
2022Eli Lilly Exits US Insulin Pump Joint Venture With Ypsomed
MT
More news
Analyst Recommendations on YPSOMED HOLDING AG
More recommendations
Financials
Sales 2023 513 M 556 M 556 M
Net income 2023 45,2 M 49,0 M 49,0 M
Net Debt 2023 134 M 145 M 145 M
P/E ratio 2023 58,3x
Yield 2023 0,71%
Capitalization 2 490 M 2 696 M 2 696 M
EV / Sales 2023 5,11x
EV / Sales 2024 4,73x
Nbr of Employees 2 000
Free-Float 31,6%
Chart YPSOMED HOLDING AG
Duration : Period :
Ypsomed Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends YPSOMED HOLDING AG
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 182,40 CHF
Average target price 223,33 CHF
Spread / Average Target 22,4%
EPS Revisions
Managers and Directors
Simon Michel Chief Executive Officer & Director
Niklaus Ramseier Chief Financial Officer
Gilbert Achermann Chairman
Hans Ulrich Lehmann Senior Vice President-Technology
Frank Mengis Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
YPSOMED HOLDING AG9.24%2 714
ABBOTT LABORATORIES1.82%193 101
MEDTRONIC PLC12.07%113 385
BECTON, DICKINSON AND COMPANY-1.63%71 021
DEXCOM, INC.-5.75%41 225
HOYA CORPORATION12.04%38 235